RxDoctor Payments Data

Jeffrey Vanmeter, MD

Family Medicine · Somerset, OHNPI 1073599262

Payments from drug & device makers

$12,608in general payments, 2019–2025

Across 824 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$1K
  • GSK$942
  • Amgen$800
  • Bayer$785
  • Merck$745
  • plus $6K from 31 others

What the payments were for

  • Food & beverage$12,51399%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,608 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$64,536
Medicare patients
185
Services billed
1,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol134$143,274
JardianceEmpagliflozin129$121,103
OzempicSemaglutide65$86,555
EliquisApixaban89$62,657
MounjaroTirzepatide52$55,068
XareltoRivaroxaban38$47,376
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$43,914
JanuviaSitagliptin Phosphate37$30,836
RybelsusSemaglutide16$20,850
VascepaIcosapent Ethyl31$20,173
Spiriva RespimatTiotropium Bromide17$17,672
KerendiaFinerenone16$16,690
LinzessLinaclotide22$15,834
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,352
EntrestoSacubitril/Valsartan12$8,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$2,721$164,907175 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$651$144,368158 claims
Novo NordiskOzempic, Rybelsus$603$107,40681 claims
PfizerEliquis$363$62,65789 claims
Lilly USA, LLCMounjaro$696$55,06852 claims
Johnson & JohnsonXarelto$448$47,37638 claims
GSKTrelegy Ellipta$942$43,91439 claims
MerckJanuvia$745$30,83637 claims
BayerKerendia$785$16,69016 claims
AbbVieLinzess$1,037$15,83422 claims
NovartisEntresto$173$8,10012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Somerset

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →